169 related articles for article (PubMed ID: 19814673)
21. Drug evaluation: Deferitrin for iron overload disorders.
Barton JC
IDrugs; 2007 Jul; 10(7):480-90. PubMed ID: 17642018
[TBL] [Abstract][Full Text] [Related]
22. Thalassemia incidence and treatment in China with special reference to Shenzhen City and Guangdong province.
Li CG; Li CF; Li Q; Li M
Hemoglobin; 2009; 33(5):296-303. PubMed ID: 19814675
[TBL] [Abstract][Full Text] [Related]
23. Drug evaluation: deferitrin (GT-56-252; NaHBED) for iron overload disorders.
Barton JC
IDrugs; 2007 Apr; 10(4):270-81. PubMed ID: 17390251
[TBL] [Abstract][Full Text] [Related]
24. Assessment and treatment of cardiac iron overload in thalassemia.
Aessopos A; Farmakis D; Andreopoulos A; Tsironi M
Hemoglobin; 2009; 33 Suppl 1():S87-92. PubMed ID: 20001638
[TBL] [Abstract][Full Text] [Related]
25. The role of antioxidants and iron chelators in the treatment of oxidative stress in thalassemia.
Fibach E; Rachmilewitz EA
Ann N Y Acad Sci; 2010 Aug; 1202():10-6. PubMed ID: 20712766
[TBL] [Abstract][Full Text] [Related]
26. Guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload.
Gattermann N
Leuk Res; 2007 Dec; 31 Suppl 3():S10-5. PubMed ID: 18037413
[TBL] [Abstract][Full Text] [Related]
27. Proceedings of the 18th International Conference on Chelation (ICOC). December 13-16, 2008, Athens, Greece.
Hemoglobin; 2010 Jun; 34(3):199-331. PubMed ID: 21305716
[No Abstract] [Full Text] [Related]
28. Preclinical and clinical development of deferitrin, a novel, orally available iron chelator.
Donovan JM; Plone M; Dagher R; Bree M; Marquis J
Ann N Y Acad Sci; 2005; 1054():492-4. PubMed ID: 16339704
[TBL] [Abstract][Full Text] [Related]
29. Controversies surrounding iron chelation therapy for MDS.
Leitch HA
Blood Rev; 2011 Jan; 25(1):17-31. PubMed ID: 21030120
[TBL] [Abstract][Full Text] [Related]
30. Iron absorption in non-transfused iron loading anaemias: prediction of risk for iron loading, and response to iron chelation treatment, in beta thalassaemia intermedia and congenital sideroblastic anaemias.
Pippard MJ; Weatherall DJ
Haematologia (Budap); 1984; 17(1):17-24. PubMed ID: 6724353
[TBL] [Abstract][Full Text] [Related]
31. The proceedings of the 20th International Conference on Chelation held in the USA: advances on new and old chelation therapies.
Kontoghiorghes GJ
Toxicol Mech Methods; 2013 Jan; 23(1):1-4. PubMed ID: 22900514
[TBL] [Abstract][Full Text] [Related]
32. Report on the proceedings of the 15th International Conference on Oral Chelation (ICOC) in the Treatment of Thalassemia and Other Diseases at Taichung, Taiwan, April 22-26, 2005.
Peng CT; Fucharoen S; Kontoghiorghes GJ; Tsai CH
Hemoglobin; 2006; 30(1):63-8. PubMed ID: 16540418
[No Abstract] [Full Text] [Related]
33. Chemical features of in use and in progress chelators for iron overload.
Nurchi VM; Crisponi G; Lachowicz JI; Medici S; Peana M; Zoroddu MA
J Trace Elem Med Biol; 2016 Dec; 38():10-18. PubMed ID: 27365273
[TBL] [Abstract][Full Text] [Related]
34. Treating iron overload in patients with non-transfusion-dependent thalassemia.
Taher AT; Viprakasit V; Musallam KM; Cappellini MD
Am J Hematol; 2013 May; 88(5):409-15. PubMed ID: 23475638
[TBL] [Abstract][Full Text] [Related]
35. Iron Overload and Chelation Therapy in Non-Transfusion Dependent Thalassemia.
Bou-Fakhredin R; Bazarbachi AH; Chaya B; Sleiman J; Cappellini MD; Taher AT
Int J Mol Sci; 2017 Dec; 18(12):. PubMed ID: 29261151
[TBL] [Abstract][Full Text] [Related]
36. Thalassemia.
Aydinok Y
Hematology; 2012 Apr; 17 Suppl 1():S28-31. PubMed ID: 22507773
[TBL] [Abstract][Full Text] [Related]
37. Thalassemia: an overview of 50 years of clinical research.
Sankaran VG; Nathan DG
Hematol Oncol Clin North Am; 2010 Dec; 24(6):1005-20. PubMed ID: 21075277
[TBL] [Abstract][Full Text] [Related]
38. Thalassaemia in children: from quality of care to quality of life.
Amid A; Saliba AN; Taher AT; Klaassen RJ
Arch Dis Child; 2015 Nov; 100(11):1051-7. PubMed ID: 26289062
[TBL] [Abstract][Full Text] [Related]
39. Iron chelation therapy in hereditary hemochromatosis and thalassemia intermedia: regulatory and non regulatory mechanisms of increased iron absorption [Kontoghiorghes GJ, Spyrou A, Kolganou A. Hemoglobin. 2010;34(3); 251-264].
Nick HP
Hemoglobin; 2011; 35(2):175-9. PubMed ID: 21417578
[No Abstract] [Full Text] [Related]
40. New concept in natural history and management of diabetes mellitus in thalassemia major.
Chatterjee R; Bajoria R
Hemoglobin; 2009; 33 Suppl 1():S127-30. PubMed ID: 20001615
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
